The role and mechanism of rosiglitazone in endothelial-to-mesenchymal transition in pulmonary hypertension.
OBJECTIVE Pulmonary hypertension (PH) involves endothelial-to-mesenchymal transition (EndMT) in vascular remodeling. Rosiglitazone (RSG), a peroxisome proliferator-activated receptor gamma agonist, alleviates PH, but its direct effect on EndMT is unclear. The study explores RSG's role and mechanism in inhibiting EndMT....